Dexamethasone sustained-release - Taiwan Liposomal Company

Drug Profile

Dexamethasone sustained-release - Taiwan Liposomal Company

Alternative Names: TLC-599

Latest Information Update: 24 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Taiwan Liposome Company
  • Class Anti-inflammatories; Antiemetics; Antineoplastics; Corticosteroids; Fluorinated steroids; Glucocorticoids; Pregnadienetriols; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Osteoarthritis

Most Recent Events

  • 23 Jan 2018 Dexamethasone sustained release licensed to TLC Biopharmaceuticals in China
  • 11 Jul 2017 Taiwan Liposomal Company receives US patent covering dexamethasone sustained-release
  • 16 Mar 2017 Phase-II clinical trials in Osteoarthritis (In the elderly, In adults) in Australia and Taiwan (Intra-articular) (NCT03005873)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top